Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects

Journal of Immunology

Volumn 183, Issue 5, 2009, Pages 3081-3091

  Zhang, Zhiren ^a   Zhang, Zhi Yuan ^a   Schluesener, Hermann J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; COMPOUND A; CYTOKINE; INTERLEUKIN 1BETA; MESSENGER RNA; PREDNISOLONE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2 (4 ACETOXYPHENYL) 2 CHLORO N METHYLETHYLAMINE; 2-(4-ACETOXYPHENYL)-2-CHLORO-N-METHYLETHYLAMINE; ACETIC ACID DERIVATIVE; ETHYLAMINE; GLUCOCORTICOID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; BLOOD; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; DEMYELINATION; DRUG EFFECT; DRUG MECHANISM; IMMUNIZATION; IN VITRO STUDY; INFLAMMATION; LYMPH NODE; MACROPHAGE; MALE; MICROGLIA; NEURITIS; NEUROPATHIC PAIN; NONHUMAN; PARAPLEGIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; SCIATIC NERVE; SPINAL CORD; TH1 CELL; TH17 CELL; UPREGULATION; ANIMAL; CELL LINE; CELL PROLIFERATION; CHEMISTRY; DISEASE COURSE; DOWN REGULATION; DRUG POTENTIATION; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; SALSOLA;

ACETATES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TRANSFORMED; CELL PROLIFERATION; DISEASE PROGRESSION; DOWN-REGULATION; ETHYLAMINES; MACROPHAGES; MALE; MICE; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; RATS; RECEPTORS, GLUCOCORTICOID; SALSOLA; T-LYMPHOCYTES, REGULATORY; UP-REGULATION;

EID: 70349247894     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901088     Document Type: Article

References (53)

1. Hughes, R. A., and D. R. Cornblath. 2005. Guillain-Barre syndrome. Lancet 366: 1653-1666.
2. Hughes, R. A. 2002. Systematic reviews of treatment for inflammatory demyelinating neuropathy. J. Anat. 200: 331-339.
3. Kieseier, B. C., R. Kiefer, R. Gold, B. Hemmer, H. J. Willison, and H. P. Hartung. 2004. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30: 131-156.
4. Winer, J. B. 2001. Guillain Barre syndrome. Mol. Pathol. 54: 381-385.
5. Zhang, Z., Z. Y. Zhang, U. Fauser, and H. J. Schluesener. 2008. Mechanical allodynia and spinal up-regulation of P2X4 receptor in experimental autoimmune neuritis rats. Neuroscience 152: 495-501.
6. Gold, R., J. J. Archelos, and H. P. Hartung. 1999. Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol. 9: 343-360.
7. Wilson, C. B., E. Rowell, and M. Sekimata. 2009. Epigenetic control of T-helper-cell differentiation. Nat. Rev. Immunol. 9: 91-105.
8. Zhang, Z. Y., Z. Zhang, and H. J. Schluesener. 2009. FTY720 attenuates lesional interleukin-17 cell accumulation in rat experimental autoimmune neuritis. Neuropathol. Appl. Neurobiol. In press.
9. + T-regulatory cells in experimental autoimmune neuritis rats. Exp. Neurol. 216: 75-82.
10. Kiefer, R., B. C. Kieseier, G. Stoll, and H. P. Hartung. 2001. The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog. Neurobiol. 64: 109-127.
11. Maurer, M., K. V. Toyka, and R. Gold. 2002. Cellular immunity in inflammatory autoimmune neuropathies. Rev. Neurol. 158: S7-S15.
12. Craggs, R. I., R. H. King, and P. K. Thomas. 1984. The effect of suppression of macrophage activity on the development of experimental allergic neuritis. Acta Neuropathol. 62: 316-323.
13. Ricardo, S. D., H. van Goor, and A. A. Eddy. 2008. Macrophage diversity in renal injury and repair. J. Clin. Invest. 118: 3522-3530.
14. Mosser, D. M., and J. P. Edwards. 2008. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8: 958-969.
15. Barnes, P. J. 2006. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br. J. Pharmacol. 148: 245-254.
16. Schacke, H., W. D. Docke, and K. Asadullah. 2002. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96: 23-43.
17. Stahn, C., M. Lowenberg, D. W. Hommes, and F. Buttgereit. 2007. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol. Cell Endocrinol. 275: 71-78. (Pubitemid 47259281)
18. Rosen, J., and J. N. Miner. 2005. The search for safer glucocorticoid receptor ligands. Endocr. Rev. 26: 452-464.
19. Reichardt, H. M., K. H. Kaestner, O. Wessely, P. Gass, W. Schmid, and G. Schutz. 1998. Analysis of glucocorticoid signalling by gene targeting. J. Steroid Biochem. Mol. Biol. 65: 111-115.
20. Reichardt, H. M., J. P. Tuckermann, M. Gottlicher, M. Vujic, F. Weih, P. Angel, P. Herrlich, and G. Schutz. 2001. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 20: 7168-7173.
21. Louw, A., and P. Swart. 1999. Salsola tuberculatiformis Botschantzev and an aziridine precursor analog mediate the in vivo increase in free corticosterone and decrease in corticosteroid-binding globulin in female Wistar rats. Endocrinology 140: 2044-2053. (Pubitemid 30636441)
22. De Bosscher, K., W. Vanden Berghe, I. M. Beck, W. Van Molle, N. Hennuyer, J. Hapgood, C. Libert, B. Staels, A. Louw, and G. Haegeman. 2005. A fully dissociated compound of plant origin for inflammatory gene repression. Proc. Natl. Acad. Sci. USA 102: 15827-15832.
23. Dewint, P., V. Gossye, K. De Bosscher, W. Vanden Berghe, K. Van Beneden, D. Deforce, S. Van Calenbergh, U. Muller-Ladner, B. Vander Cruyssen, G. Verbruggen, et al. 2008. A plant-derived ligand favoring monomeric glucocorticoid receptor conformation with impaired transactivation potential attenuates collagen-induced arthritis. J. Immunol. 180: 2608-2615.
24. Zhang, Z., Z. Y. Zhang, U. Fauser, and H. J. Schluesener. 2008. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp. Neurol. 210: 681-690.
25. Hartung, H. P., B. Schafer, K. Heininger, G. Stoll, and K. V. Toyka. 1988. The role of macrophages and eicosanoids in the pathogenesis of experimental allergic neuritis: serial clinical, electrophysiological, biochemical and morphological observations. Brain 111 (Pt. 5): 1039-1059.
26. Moestrup, S. K., and H. J. Moller. 2004. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann. Med. 36: 347-354.
27. Badylak, S. F., J. E. Valentin, A. K. Ravindra, G. P. McCabe, and A. M. Stewart-Akers. 2008. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng. Part A 14: 1835-1842.
28. Kassel, O., and P. Herrlich. 2007. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects. Mol. Cell Endocrinol. 275: 13-29.
29. Schmid, E., W. Schmid, M. Jantzen, D. Mayer, B. Jastorff, and G. Schutz. 1987. Transcription activation of the tyrosine aminotransferase gene by glucocorticoids and cAMP in primary hepatocytes. Eur. J. Biochem. 165: 499-506.
30. Ruppert, S., M. Boshart, F. X. Bosch, W. Schmid, R. E. Fournier, and G. Schutz. 1990. Two genetically defined trans-acting loci coordinately regulate overlapping sets of liver-specific genes. Cell 61: 895-904.
31. Marzban, L., R. Rahimian, R. W. Brownsey, and J. H. McNeill. 2002. Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo. Endocrinology 143: 4636-4645.
32. Schabet, M., J. N. Whitaker, K. Schott, A. Stevens, A. Zurn, R. Buhler, and H. Wietholter. 1991. The use of protease inhibitors in experimental allergic neuritis. J. Neuroimmunol. 31: 265-272.
33. Bettelli, E., T. Korn, M. Oukka, and V. K. Kuchroo. 2008. Induction and effector functions of TH17 cells. Nature 453: 1051-1057.
34. Dong, C. 2008. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8: 337-348.
35. Zhu, J., X. F. Bai, E. Mix, and H. Link. 1997. Cytokine dichotomy in peripheral nervous system influences the outcome of experimental allergic neuritis: dynamics of mRNA expression for IL-1 β, IL-6, IL-10, IL-12, TNF-α, TNF-β, and cytolysin. Clin. Immunol. Immunopathol. 84: 85-94.
36. Abramson, S. B., A. R. Amin, R. M. Clancy, and M. Attur. 2001. The role of nitric oxide in tissue destruction. Best Pract. Res. Clin. Rheumatol. 15: 831-845.
37. Conti, G., A. Rostami, E. Scarpini, P. Baron, D. Galimberti, N. Bresolin, M. Contri, C. Palumbo, and A. De Pol. 2004. Inducible nitric oxide synthase (iNOS) in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. Exp. Neurol. 187: 350-358.
38. Moulin, D. E., N. Hagen, T. E. Feasby, R. Amireh, and A. Hahn. 1997. Pain in Guillain-Barre syndrome. Neurology 48: 328-331.
39. Ji, R. R., and G. Strichartz. 2004. Cell signaling and the genesis of neuropathic pain. Sci STKE 2004: reE14.
40. Watkins, L. R., and S. F. Maier. 2002. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiol. Rev. 82: 981-1011.
41. Beiter, T., M. R. Artelt, K. Trautmann, and H. J. Schluesener. 2005. Experimental autoimmune neuritis induces differential microglia activation in the rat spinal cord. J. Neuroimmunol. 160: 25-31.
42. Moalem, G., and D. J. Tracey. 2006. Immune and inflammatory mechanisms in neuropathic pain. Brain Res. Rev. 51: 240-264.
43. Raghavendra, V., F. Tanga, and J. A. DeLeo. 2003. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J. Pharmacol. Exp. Ther. 306: 624-630.
44. Steinman, L. 2007. A brief history of TH17, the first major revision in the TH1/ TH2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13: 139-145.
45. Rautajoki, K. J., M. K. Kylaniemi, S. K. Raghav, K. Rao, and R. Lahesmaa. 2008. An insight into molecular mechanisms of human T helper cell differentiation. Ann. Med. 40: 322-335.
46. Zheng, Y., and A. Y. Rudensky. 2007. Foxp3 in control of the regulatory T cell lineage. Nat. Immunol. 8: 457-462.
47. + regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9: 239-244.
48. + regulatory T cells in murine models of organ-specific autoimmune disease. Cell Immunol. 251: 8-18.
49. + T cells in the periphery. Nat. Rev. Immunol. 7: 231-237.
50. Wu, K., Y. Bi, K. Sun, and C. Wang. 2007. IL-10-producing type 1 regulatory T cells and allergy. Cell Mol. Immunol. 4: 269-275.
51. + T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur. J. Immunol. 36: 2139-2149.
52. Nakae, J., T. Kitamura, D. L. Silver, and D. Accili. 2001. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J. Clin. Invest. 108: 1359-1367.
53. Opherk, C., F. Tronche, C. Kellendonk, D. Kohlmuller, A. Schulze, W. Schmid, and G. Schutz. 2004. Inactivation of the glucocorticoid receptor in hepatocytes leads to fasting hypoglycemia and ameliorates hyperglycemia in streptozotocin-induced diabetes mellitus. Mol. Endocrinol. 18: 1346-1353.